Description

Indication & Scope

Dorzagliatin Tablets (MYHOMSIS) is an oral glucose homeostasis regulator indicated to improve glycemic control in adult patients with type 2 diabetes mellitus. It can be used as monotherapy combined with diet and exercise for treatment-naive patients, or combined with metformin for patients with inadequate glycemic control on metformin alone.

Mechanism
As an allosteric full activator of glucokinase (GK), it targets GK in pancreatic islets, intestinal endocrine cells and liver. It restores impaired glucose-sensing function, boosts glucose-stimulated insulin and GLP-1 secretion, alleviates insulin resistance and reconstructs physiological blood glucose steady-state regulation.
Drug class
Class 1 innovative chemical drug, first-in-class oral glucokinase activator (GKA), novel anti-diabetic agent for type 2 diabetes.
Clinical use
Clinical use
Phase III clinical trials demonstrated significant HbA1c reduction and favorable safety profile with extremely low hypoglycemia risk. Clinically administered orally at 75 mg twice daily within 1 hour before breakfast and dinner. It is the world’s first approved GKA independently developed in China.

Specification

Generic Name	Dorzagliatin Tablets
Brand Name	Huangtangning®
Ingredient	Dorzagidn
Dosage Form	Film-coated Tablets
Package	75mg/box
Conditions Treated	Improving glycemic control in adults with type 2 diabetes mellitus; used alone with diet and exercise for newly diagnosed patients, or combined with metformin for patients with poor blood glucose control on metformin
Taboos	Patients with hypersensitivity to dorzagliatin or any excipients of this product
Place of origin	Shanghai, China
Priscription Type	Prescription drug (Rx)
Storage Conditions	Sealed, store below 30℃
Manufacturer	Hua Medicine (Shanghai) Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	H20220024
Date of Revision	December 20, 2023
Shelf Life	24 months

How to use ?

Recommended Dose: 75 mg twice daily, taken within one hour before breakfast and dinner. Adjust dosage according to individual blood glucose response if needed, maximum daily dose is 150 mg.

Time: Take orally before meals on a regular schedule; can be used long-term for sustained glycemic control in type 2 diabetes patients.

Interaction: May be used as monotherapy with diet and exercise, or combined with metformin. Avoid use with drugs that cause severe hypoglycemia without close blood glucose monitoring. Not for intravenous administration.

Side effects: Mostly mild and transient; common ones include dizziness, diarrhea, nausea, elevated blood lipids. Rare hypoglycemia, abnormal liver function indicators; severe hypersensitivity reactions are extremely uncommon.

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support